Clinical Trials Logo
  1. Home
  2. Carcinoma, Ovarian Epithelial
  3. NCT05158062

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Carcinoma, Ovarian Epithelial Clinical Trial

Official title:
Phase II Study of Pembrolizumab and Bevacizumab in Combination With Platinum-based Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Clinical Trial Summary

This trial is a multicenter, single-arm, phase II study evaluating the efficacy of pembrolizumab and bevacizumab in combination with platinum-based chemotherapy (PBC) followed by pembrolizumab, bevacizumab and olaparib as a maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer.This study is planned to enroll eligible 35 patients from multiple study sites in Japan.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05158062
Study type Interventional
Source Saitama Medical University International Medical Center
Contact Kosei Hasegawa, MD, PhD
Phone +81-42-984-4111
Email koseih@saitama-med.ac.jp
Status Recruiting
Phase Phase 2
Start date April 20, 2022
Completion date November 30, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05601700 - Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) Phase 3
Recruiting NCT06121401 - First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients Phase 4
Recruiting NCT04566952 - Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Phase 2
Recruiting NCT05544929 - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers Phase 1
Recruiting NCT04556071 - Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer Phase 2
Recruiting NCT05617755 - AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer Phase 1
Not yet recruiting NCT04807166 - Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer Phase 2
Recruiting NCT03976999 - Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers N/A
Active, not recruiting NCT04660929 - CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors Phase 1
Active, not recruiting NCT05116189 - Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) Phase 3
Active, not recruiting NCT04498117 - Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery Phase 3
Recruiting NCT04196257 - BP1001-A in Patients With Advanced or Recurrent Solid Tumors Phase 1
Recruiting NCT04519151 - Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer Phase 2